Action of cortisone and cortisol upon biosynthesis of chondroitin sulfate in femur in vitro cultures of chick embryo

Combination material delivery of dexamethasone and growth factor in hydrogel blended with hyaluronic acid constructs for neocartilage formation

The aim of this study was to assess the efficacy of poly(NiPAAm-co-AAc) blended with hyaluronic acid (HA) as an injectable cell vehicle and a cell therapeutic agent in the form of a supporting matrix for the chondrogenic differentiation of rabbit chondrocytes. Specially, rabbit chondrocytes were embedded in blended hydrogels co-encapsulation with dexamethasone (Dex) and growth factors for enhancing the chondrogenic differentiation. Blended hydrogel constructs consisting of embedded cells co-encapsulating Dex and TGF beta-3 or unloaded Dex and sTGF beta-3 served as controls to assess the effects of Dex on chondrogenic differentiation. Hydrogel constructs consisting of embedded cells co-encapsulating Dex and TGF beta-3 on chondrogenic differentiation. The hydrogel constructs were injected subcutaneously into the nude mice and monitored for 1, 4, and 8 weeks after the injection. The level of the cartilage-associated ECM proteins was determined by immunohistochemical (collagen type II; specific marker for chondrogenic differentiation), Safranin-O, and Alcian blue (GAG) staining. Over the same time period, the glycosamingoglycan content per cell remained constant for all formulations, indicating that the dramatic increase in cell number for samples with Dex and TGF beta-3 loaded in hydrogel constructs was accompanied by maintenance of the cell phenotypes.

Enhancement of cell proliferation and differentiation by combination of ascorbate and dexamethasone in thermo-reversible hydrogel constructs embedded with rabbit chondrocytes

The effects of inducible materials (dexamethasone and ascorbate) on chondrogenic differentiation of rabbit chondrocytes have been examined. A hydrogel construct containing dexamethasone and ascorbate up-regulated gene expression of the cartilage matrix component of collagen to give three times the collagen content per construct at day 56 as compared to controls. Alcian Blue and Safranin-O staining revealed that these constructs also had formed more hyaline cartilage than other hydrogel constructs.

Delivery of dexamethasone, ascorbate, and growth factor (TGF β-3) in thermo-reversible hydrogel constructs embedded with rabbit chondrocytes

The aim of this study was to assess the efficacy of poly(N-isopropylacrylamide-co-acrylic acid) (p(NiPAAm-co-AAc)) as an injectable drug delivery vehicle and a cell therapeutic agent in the form of a supporting matrix for the chondrogenic differentiation of rabbit chondrocytes. The p(NiPAAm-co-AAc) hydrogel itself without specific differentiation-inducing drugs was used as a control in order to determine the effects of these materials on chondrogenic differentiation. The level of cartilage associated extracellular matrix (ECM) proteins was examined by immunohistochemical staining for collagen type II as well as Safranin-O and Alcian blue (GAG) staining. These results highlight the potential of a thermo-reversible hydrogel mixed with chondrocytes and differentiation materials as an injectable delivery vehicle for use in neocartilage formation.

Dexamethasone inhibits insulin-induced chondrogenesis of ATDC5 cells by preventing PI3K-Akt signaling and DNA binding of Runx2

Glucocorticoids play important roles in cell growth and differentiation. In this study, we investigated the effect of application of dexamethasone (DEX) at the early stage of chondrogenesis using the prechondrogenic cell line, ATDC5, which differentiates into chondrocytes in the presence of insulin. When ATDC5 cells were cultured in the presence of DEX and insulin, DEX inhibited insulin-induced cellular condensation and subsequent cartilaginous nodule formation, and reduced proteoglycan synthesis and type II collagen expression dose-dependently. Pretreatment with 10(-8) M DEX for 1 day inhibited insulin-induced Akt phosphorylation, but not ERK1/2 phosphorylation, in ATDC5 cells. Treatment of ATDC5 cells with insulin for more than 2 days upregulated the levels of phosphatidylinositol 3-kinase (PI3K) subunit proteins, p85 and p110, and Akt, whereas the upregulation was inhibited in the presence of 10(-8) M DEX. In electrophoresis mobility shift assays (EMSAs), treatment with 10(-8) M DEX inhibited DNA binding of Runx2 during culture of ATDC5 cells with insulin. Reporter assays using osteocalcin promoter showed that DEX inhibited Runx2-dependent transcription dose-dependently. Adenoviral introduction of dominant-negative (dn)-Akt or dn-Runx2 into ATDC5 cells inhibited cellular condensation and reduced proteoglycan synthesis upon incubation with insulin, whereas adenoviral introduction of Akt or Runx2 prevented the inhibition of chondrogenesis by DEX. These findings indicate that DEX inhibits chondrogenesis of ATDC5 cells at the early stage by downregulating Akt phosphorylation as well as the protein levels of PI3K subunits and Akt, thereby suppressing PI3K-Akt signaling, and by inhibiting DNA binding of Runx2 and Runx2-dependent transcription.

Effects of insulin-like growth factor-I, corticosterone, and 3,3', 5-tri-iodo-L-thyronine on glycosaminoglycan synthesis in vertebral cartilage of the clearnose skate, Raja eglanteria

Effects of insulin-like growth factor-I (IGF-I), corticosterone, and triiodothyronine (T(3)) on in vitro growth of vertebral cartilage of the clearnose skate, Raja eglanteria, were investigated. Uptake of [(35)S]sulfate in cultured vertebrae was used to characterize glycosaminoglycan (GAG) synthesis and cartilage growth. IGF-I significantly enhanced cartilage growth when concentrations of 1.28 and 12.8 nM were present in the culture system. Corticosterone significantly inhibited vertebral GAG synthesis at concentrations of 1, 10, and 100 nM. This effect was markedly pronounced in cartilage exposed to 1 and 10 nM corticosterone, in which GAG synthesis was virtually ceased. In contrast, T(3) (0.75, 7.5, and 75.0 nM) had no significant effect on sulfate uptake. These data suggest that IGF-I and corticosteroids may play important roles in regulating skeletal growth of elasmobranchs, as they appear to do in other vertebrates. While T(3) does not appear to exert an immediate, direct effect on vertebral growth, it may still influence elasmobranch chondrogenesis over longer culture periods or indirectly through other regulatory pathways. Thus, further information is necessary to characterize the role of thyroid hormones in the skeletal growth of these fishes. The present study is the first in vitro investigation on the hormonal regulation of elasmobranch cartilage growth. As such, the methods described herein provide a useful technique for examining these physiological processes. J. Exp. Zool. 284:549-556, 1999.

Cortisol inhibits glycosaminoglycan synthesis in cultured rainbow trout cartilage

In vitro actions of corticosteroids (cortisol, 11-deoxycortisol, cortisone, and corticosterone) as well as interaction between cortisol and triiodothyronine (T3) or recombinant human insulin-like growth factor-I (rhIGF-I) on cartilage glycosaminoglycan (GAG) synthesis in rainbow trout (Oncorhynchus mykiss) were examined. Uptake of [35S]sulfate by isolated branchial cartilage was measured as a marker for GAG synthesis. In vitro exposure of cartilage to cortisol at concentrations of 10, 100, and 1000 nM for 6 days dose-dependently inhibited sulfate uptake, while exposure to 0.1 and 1 nM cortisol had no effect. Corticosterone and 11-deoxycortisol at concentrations of 10 and 100 nM inhibited sulfate uptake slightly but not dose-dependently. Cortisone (1, 10, and 100 nM) had no effect. When cortisol (1, 10, and 100 nM) and T3 (0.075 and 0.75 nM) were simultaneously added to the culture, the T3-induced sulfate uptake was dose-dependently reduced by the presence of 10 and 100 nM cortisol. When cortisol (1, 10, and 100 nM) and rhIGF-I (0.1 and 1 nM) were added together, the sulfate uptake induced by 0.1 nM rhIGF-I was only slightly inhibited by 100 nM cortisol, but 1 nM rhIGF-I completely masked the inhibitory effect of cortisol. These data suggest that GAG synthesis in the rainbow trout cartilage is controlled by multiple interactions among stimulative hormones, such as T3 and IGF-I, and inhibitory hormones, such as cortisol.

Characterization of a glucocorticoid responsive element and identification of an AT-rich element that regulate the link protein gene

The cartilage matrix is composed of characteristic components including type II collagen, aggrecan and link protein. In this paper, we report two DNA elements that regulate the link protein gene. Using transient transfection assays with link protein gene constructs in chondrocytes, chloramphenicol acetyl transferase (CAT) assays were used to measure the transcriptional activity of the link protein gene. Previously, we identified an enhancer-like activity within the first intron of the gene. In this paper, we report an active 34 bp (+1390 to +1424) fragment within this region that contains a glucocorticoid-like response element (GRE). Both deletion of, and site-specific mutations within this sequence motif reduced the dexamethasone-inducible activity. The GRE-like sequence from the rat link protein gene, or the homologous sequence from the human link protein gene were included in vectors containing the thymidine kinase promoter linked to the CAT gene (tkCAT). Both human and rat elements transferred the ability to respond to dexamethasone and hydrocortisone with a > 10-fold induction. Deletions through the promoter from -923 to -900 identified a second site required for both glucocorticoid and serum responsiveness. A four base substitution at this site resulted in a loss of serum responsiveness. This region contains an AT-rich element, similar to the AT-rich elements involved in homeotic protein regulation of the growth hormone gene and the muscle creatine kinase gene. Southwestern analysis using oligonucleotides containing the AT-rich element from the link protein gene or the muscle creatine kinase gene, identified a 32 kDa protein band from nuclear extracts of chick chondrocytes. Using these AT-rich oligonucleotides in band-shift analyses, nuclear extracts of chick sternal muscle, rat chondrosarcoma and chick sternal chondrocytes each showed formation of different complexes suggesting cell specificity. AT-rich elements have been identified as binding sites for homeodomain-containing proteins and can contribute to gene regulation by serum response factors. The identification of an AT-rich element in the link protein gene suggests similar functions for this element.

Anti-rheumatic drugs and cartilage

In this chapter an attempt has been made to draw together the known biology of cartilage and some of the mechanisms thought to be responsible for its failure in arthritis. The picture is far from complete but we are now in a good position to use this information to help appraise the pros and cons of the wide range of drugs now available to treat articular disorders. For convenience, these drugs were classified as NSAIDs, corticosteroids and chondroprotective agents. The influence of each of these classes on the metabolism of cartilage was examined in the light of published laboratory and clinical studies. It has been clearly shown that not all NSAIDs are the same. While many of the older drugs provided no benefit to cartilage metabolism, and in some instances suppressed it, the more recently discovered molecules appear to be free of these undesirable effects. Tiaprofenic acid, diclofenac and piroxicam emerged as drugs with little or no harmful effects on cartilage metabolism when used at concentrations within the human therapeutic range. For all NSAIDs, their potential effects on cartilage must be weighed against their respective anti-inflammatory potency, half-life, and effects on the gastric mucosa and other tissues. Other chapters in this book have addressed these important problems. The long-acting corticosteroids, betamethasone and triamcinolone hexacetonide, also appear to offer some benefit in the management of OA; however, as in RA, their use should be restricted to short-term applications. In terms of cartilage metabolism the chondroprotective agents pentosan polysulphate, Arteparon and Rumalon have been the most extensively studied class of drugs. While the laboratory studies have provided convincing evidence of their chondroprotective efficacy, it has been difficult to prove this clinically. This dichotomy of opinion (laboratory versus clinical) stems largely from the inadequacy of the methodologies currently available for the objective clinical assessment of patient response to anti-rheumatic drug therapy. With the advent of nuclear magnetic resonance imaging techniques and monoclonal antibodies to detect specific proteoglycan breakdown fragments in synovial fluid and plasma, the prospects for a unified research approach for the evaluation of these agents may now be possible.